These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38483480)

  • 1. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
    Vaccaro K; Allen J; Whitfield TW; Maoz A; Reeves S; Velarde J; Yang D; Meglan A; Ribeiro J; Blandin J; Phan N; Bell GW; Hata AN; Weiskopf K
    J Clin Invest; 2024 Mar; 134(9):. PubMed ID: 38483480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
    Vaccaro K; Allen J; Whitfield TW; Maoz A; Reeves S; Velarde J; Yang D; Phan N; Bell GW; Hata AN; Weiskopf K
    bioRxiv; 2023 Mar; ():. PubMed ID: 36945559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
    Hu LY; Zhuang WT; Chen MJ; Liao J; Wu DF; Zhang YX; Pang LL; Huang YH; Mao TQ; Yang MJ; Peng PJ; Liang JX; Chen L; Zeng LJ; Zhang L; Fang WF
    J Thorac Oncol; 2024 Aug; 19(8):1186-1200. PubMed ID: 38553005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
    Pan Y
    J Thorac Oncol; 2024 Oct; 19(10):e49-e50. PubMed ID: 39370221
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Commentary on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
    Zhuang WT; Hu LY; Fang WF
    J Thorac Oncol; 2024 Oct; 19(10):e50-e51. PubMed ID: 39370222
    [No Abstract]   [Full Text] [Related]  

  • 9. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
    Weiskopf K; Jahchan NS; Schnorr PJ; Cristea S; Ring AM; Maute RL; Volkmer AK; Volkmer JP; Liu J; Lim JS; Yang D; Seitz G; Nguyen T; Wu D; Jude K; Guerston H; Barkal A; Trapani F; George J; Poirier JT; Gardner EE; Miles LA; de Stanchina E; Lofgren SM; Vogel H; Winslow MM; Dive C; Thomas RK; Rudin CM; van de Rijn M; Majeti R; Garcia KC; Weissman IL; Sage J
    J Clin Invest; 2016 Jul; 126(7):2610-20. PubMed ID: 27294525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47.
    Hu H; Cheng R; Wang Y; Wang X; Wu J; Kong Y; Zhan S; Zhou Z; Zhu H; Yu R; Liang G; Wang Q; Zhu X; Zhang CY; Yin R; Yan C; Chen X
    J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36413402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
    Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
    Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer.
    Zhang X; Fan J; Wang S; Li Y; Wang Y; Li S; Luan J; Wang Z; Song P; Chen Q; Tian W; Ju D
    Cancer Immunol Res; 2017 May; 5(5):363-375. PubMed ID: 28351890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC.
    Nigro A; Ricciardi L; Salvato I; Sabbatino F; Vitale M; Crescenzi MA; Montico B; Triggiani M; Pepe S; Stellato C; Casolaro V; Dal Col J
    Front Immunol; 2019; 10():3135. PubMed ID: 32082304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.
    Zhang X; Wang Y; Fan J; Chen W; Luan J; Mei X; Wang S; Li Y; Ye L; Li S; Tian W; Yin K; Ju D
    J Immunother Cancer; 2019 Dec; 7(1):346. PubMed ID: 31829270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HDAC6 improves anti-CD47 immunotherapy.
    Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
    J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing anticancer activity of macrophages through rational drug combinations.
    Mills GB; Labrie M
    J Clin Invest; 2024 May; 134(9):. PubMed ID: 38690738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.